Engineers Gate Manager’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.6M | Sell |
92,990
-7,857
| -8% | -$1.37M | 0.22% | 109 |
|
|
2025
Q4 | $17.1M | Buy |
+100,847
| New | +$15.5M | 0.2% | 109 |
|
|
2025
Q3 | – | Sell |
-2,896
| Closed | -$307K | – | 2348 |
|
|
2025
Q2 | $307K | Sell |
2,896
-10,852
| -79% | -$1.18M | ﹤0.01% | 1714 |
|
|
2025
Q1 | $1.71M | Buy |
13,748
+5,963
| +77% | +$778K | 0.03% | 763 |
|
|
2024
Q4 | $959K | Sell |
7,785
-429
| -5% | -$50.6K | 0.02% | 1036 |
|
|
2024
Q3 | $915K | Sell |
8,214
-8,378
| -50% | -$918K | 0.02% | 1046 |
|
|
2024
Q2 | $1.77M | Sell |
16,592
-18,863
| -53% | -$2.07M | 0.04% | 608 |
|
|
2024
Q1 | $4.27M | Sell |
35,455
-16,203
| -31% | -$1.98M | 0.11% | 238 |
|
|
2023
Q4 | $6.35M | Buy |
51,658
+12,284
| +31% | +$1.53M | 0.18% | 130 |
|
|
2023
Q3 | $5.1M | Sell |
39,374
-15,494
| -28% | -$2.06M | 0.19% | 117 |
|
|
2023
Q2 | $6.8M | Buy |
54,868
+37,534
| +217% | +$5.05M | 0.26% | 77 |
|
|
2023
Q1 | $2.54M | Buy |
17,334
+12,219
| +239% | +$1.81M | 0.11% | 248 |
|
|
2022
Q4 | $815K | Sell |
5,115
-22,581
| -82% | -$3.31M | 0.05% | 604 |
|
|
2022
Q3 | $3.69M | Buy |
27,696
+22,148
| +399% | +$3.37M | 0.23% | 78 |
|
|
2022
Q2 | $866K | Buy |
5,548
+2,513
| +83% | +$387K | 0.03% | 800 |
|
|
2022
Q1 | $472K | Sell |
3,035
-4,703
| -61% | -$682K | 0.02% | 1099 |
|
|
2021
Q4 | $986K | Buy |
+7,738
| New | +$1.02M | 0.04% | 632 |
|
|
2021
Q2 | – | Sell |
-7,245
| Closed | -$1.19M | – | 1813 |
|
|
2021
Q1 | $1.19M | Buy |
7,245
+5,576
| +334% | +$918K | 0.06% | 512 |
|
|
2020
Q4 | $275K | Sell |
1,669
-376
| -18% | -$56K | 0.01% | 1344 |
|
|
2020
Q3 | $292K | Sell |
2,045
-45,671
| -96% | -$5.66M | 0.01% | 1263 |
|
|
2020
Q2 | $5.26M | Buy |
47,716
+45,568
| +2,121% | +$5.04M | 0.27% | 56 |
|
|
2020
Q1 | $214K | Sell |
2,148
-7,923
| -79% | -$1.02M | 0.02% | 1225 |
|
|
2019
Q4 | $1.5M | Sell |
10,071
-46,893
| -82% | -$6.38M | 0.07% | 471 |
|
|
2019
Q3 | $7.3M | Buy |
56,964
+50,402
| +768% | +$6.76M | 0.37% | 41 |
|
|
2019
Q2 | $935K | Sell |
6,562
-6,432
| -49% | -$864K | 0.05% | 523 |
|
|
2019
Q1 | $1.86M | Sell |
12,994
-64,041
| -83% | -$8.35M | 0.11% | 273 |
|
|
2018
Q4 | $9.55M | Buy |
77,035
+38,359
| +99% | +$5.69M | 0.76% | 2 |
|
|
2018
Q3 | $6.5M | Buy |
+38,676
| New | +$6.65M | 0.5% | 31 |
|
|
2017
Q3 | – | Sell |
-16,752
| Closed | -$2.6M | – | 754 |
|
|
2017
Q2 | $2.6M | Buy |
+16,752
| New | +$2.56M | 0.23% | 155 |
|
|
2017
Q1 | – | Sell |
-29,474
| Closed | -$3.21M | – | 691 |
|
|
2016
Q4 | $3.21M | Buy |
29,474
+17,128
| +139% | +$1.91M | 0.34% | 98 |
|
|
2016
Q3 | $1.5M | Sell |
12,346
-39,711
| -76% | -$5.35M | 0.16% | 243 |
|
|
2016
Q2 | $7.36M | Buy |
52,057
+11,738
| +29% | +$1.73M | 0.53% | 7 |
|
|
2016
Q1 | $5.26M | Buy |
40,319
+14,213
| +54% | +$1.77M | 0.41% | 23 |
|
|
2015
Q4 | $3.67M | Buy |
26,106
+22,258
| +578% | +$3.08M | 0.25% | 154 |
|
|
2015
Q3 | $511K | Buy |
+3,848
| New | +$663K | 0.04% | 447 |
|
|
2015
Q2 | – | Sell |
-2,049
| Closed | -$354K | – | 1098 |
|
|
2015
Q1 | $354K | Buy |
+2,049
| New | +$352K | 0.05% | 653 |
|
Other funds holding JAZZ
VPM
VCM
EC
Engineers Gate Manager's JAZZ Position: Q1 2026 in Review
Engineers Gate Manager reduced its Jazz Pharmaceuticals (JAZZ) stake by 7.8% in Q1 2026, selling an estimated $1.37M and leaving 92,990 shares worth $17.6M. The position accounts for 0.22% of the portfolio, ranked #109.
Engineers Gate Manager first reported a position in JAZZ in Q1 2015 and has held it in 36 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Engineers Gate Manager held 92,990 shares of Jazz Pharmaceuticals worth $17.6M as of Q1 2026.
- Engineers Gate Manager sold 7,857 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.37M.
- Jazz Pharmaceuticals made up 0.22% of Engineers Gate Manager's portfolio in Q1 2026, its #109 holding.
- Engineers Gate Manager first reported a position in Jazz Pharmaceuticals in Q1 2015 and has held it in 36 quarters since.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.